Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection

被引:11
作者
Santimaleeworagun, Wichai [1 ,2 ]
Changpradub, Dhitiwat [3 ]
Thunyaharn, Sudaluck [4 ]
Hemapanpairoa, Jatapat [5 ]
机构
[1] Silpakorn Univ, Fac Pharm, Dept Pharm, Nakhon Pathom 73000, Thailand
[2] Pharmaceut Initiat Resistant Bacteria & Infect Di, Nakhon Pathom 73000, Thailand
[3] Phramongkutklao Hosp, Dept Med, Div Infect Dis, Bangkok 10400, Thailand
[4] Nakhonratchasima Coll, Fac Med Technol, Nakhon Ratchasima 30000, Thailand
[5] Burapha Univ, Fac Pharmaceut Sci, Dept Pharm Practice & Pharmaceut Care, Chon Buri 20131, Thailand
来源
ANTIBIOTICS-BASEL | 2019年 / 8卷 / 04期
关键词
daptomycin; Enterococcus faecium; MIC; Monte Carlo simulation; VRE; CLINICAL-PRACTICE GUIDELINES; DISEASES SOCIETY; DIAGNOSIS; MANAGEMENT; OUTCOMES; PHARMACOKINETICS; BACTEREMIA; UPDATE;
D O I
10.3390/antibiotics8040245
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Daptomycin, a lipopeptide antibiotic, is one of the therapeutic options used for the treatment of vancomycin-resistant enterococci (VRE). Recently, the Clinical and Laboratory Standards Institute (CLSI) M100 30th edition has removed the susceptibility (S) breakpoint for Enterococcus faecium and replaced it with a susceptible dose-dependent (SDD) breakpoint of <= 4 mu g/mL, with a suggested dosage of 8-12 mg/kg/day. Herein, we aimed to determine the minimum inhibitory concentration (MIC) values of daptomycin against clinical VRE isolates and to study the appropriate daptomycin dosing regimens among critically ill patients based on the new susceptibility CLSI breakpoint. The MIC determination of daptomycin was performed using E-test strips among clinical VRE strains isolated from patients at the Phramongkutklao Hospital. We used Monte Carlo simulation to calculate the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of the ratio of the free area under the curve to MIC (fAUC(0-24)/MIC) > 27.4 and fAUC(0-24)/MIC > 20 for survival and microbiological response, respectively, at the first day and steady state. Further, we determined that the simulated daptomycin dosing regimen met the minimum concentration (Cmin) requirements for safety of being below 24.3 mg/L. All of the 48 VRE isolates were E. faecium strains, and the percentiles at the 50th and 90th MIC of daptomycin were 1 and 1.5 mu g/mL, respectively. At MIC <= 2 mu g/mL, a daptomycin dosage of 12 mg/kg/day achieved the PTA target of survival and microbiological response at the first 24 h time point and steady state. For a MIC of 4 mu g/mL, none of the dosage regimens achieved the PTA target. For CFR, a dosage of 8-12 mg/kg/day could achieve the 90% CFR target at the first day and steady state. All dosing regimens had a low probability of Cmin being greater than 24.3 mg/L. In conclusion, the MIC of VRE against daptomycin is quite low, and loading and maintenance doses with 8 mg/kg/day were determined to be optimal and safe.
引用
收藏
页数:9
相关论文
共 34 条
[2]  
[Anonymous], 2018, J BASIC CLIN PHARM
[3]   Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint [J].
Avery, Lindsay M. ;
Kuti, Joseph L. ;
Weisser, Maja ;
Egli, Adrian ;
Rybak, Michael J. ;
Zasowski, Evan J. ;
Arias, Cesar A. ;
Contreras, German A. ;
Chong, Pearlie P. ;
Aitken, Samuel L. ;
DiPippo, Adam J. ;
Wang, Jann-Tay ;
Britt, Nicholas S. ;
Nicolau, David P. .
CLINICAL INFECTIOUS DISEASES, 2019, 68 (10) :1650-1657
[4]   Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications A Scientific Statement for Healthcare Professionals From the American Heart Association [J].
Baddour, Larry M. ;
Wilson, Walter R. ;
Bayer, Arnold S. ;
Fowler, Vance G., Jr. ;
Tleyjeh, Imad M. ;
Rybak, Michael J. ;
Barsic, Bruno ;
Lockhart, Peter B. ;
Gewitz, Michael H. ;
Levison, Matthew E. ;
Bolger, Ann F. ;
Steckelberg, James M. ;
Baltimore, Robert S. ;
Fink, Anne M. ;
O'Gara, Patrick ;
Taubert, Kathryn A. .
CIRCULATION, 2015, 132 (15) :1435-1486
[5]   2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa [J].
Berbari, Elie F. ;
Kanj, Souha S. ;
Kowalski, Todd J. ;
Darouiche, Rabih O. ;
Widmer, Andreas F. ;
Schmitt, Steven K. ;
Hendershot, Edward F. ;
Holtom, Paul D. ;
Huddleston, Paul M. ;
Petermann, Gregory W. ;
Osmon, Douglas R. .
CLINICAL INFECTIOUS DISEASES, 2015, 61 (06) :E26-E46
[6]   Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis [J].
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Ambrose, Paul G. ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (12) :1568-1574
[7]   Pharmacokinetic changes in critical illness [J].
Boucher, Bradley A. ;
Wood, G. Christopher ;
Swanson, Joseph M. .
CRITICAL CARE CLINICS, 2006, 22 (02) :255-+
[8]   Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients [J].
Britt, Nicholas S. ;
Potter, Emily M. ;
Patel, Nimish ;
Steed, Molly E. .
CLINICAL INFECTIOUS DISEASES, 2017, 64 (05) :605-613
[9]   Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever [J].
Bubalo, Joseph S. ;
Munar, Myrna Y. ;
Cherala, Ganesh ;
Hayes-Lattin, Brandon ;
Maziarz, Richard .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) :428-434
[10]   A potential role for daptomycin in enterococcal infections: what is the evidence? [J].
Canton, Rafael ;
Ruiz-Garbajosa, Patricia ;
Chaves, Ricardo L. ;
Johnson, Alan P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (06) :1126-1136